

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 January 2023 (26.01.2023)



(10) International Publication Number
WO 2023/004102 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2022/037992

(22) International Filing Date:
22 July 2022 (22.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/225,407 23 July 2021 (23.07.2021) US
63/329,237 08 April 2022 (08.04.2022) US

(71) Applicants: **THERAS, INC.** [US/US]; 421 Kipling Street, Palo Alto, California 94301 (US). **LEIDOS BIOMEDICAL RESEARCH, INC.** [US/US]; P.O. Box B, 1050 Boyles Street, Frederick, Maryland 21702 (US). **LAWRENCE LIVERMORE NATIONAL SECURITY, LLC** [US/US]; 7000 East Avenue, P.O. Box 808, L-703, Livermore, California 94550 (US).

(72) Inventors: **WANG, Bin**; c/o BridgeBio Services, Inc., 421 Kipling Street, Palo Alto, California 94301 (US). **XU, Rui**; c/o BridgeBio Services, Inc., 421 Kipling Street, Palo Alto, California 94301 (US). **WALLACE, Eli**; c/o BridgeBio Services, Inc., 421 Kipling Street, Palo Alto, California 94301 (US). **ZHANG, Zuhui**; c/o BridgeBio Services, Inc., 421 Kipling Street, Palo Alto, California 94301 (US). **TURNER, David Michael**; 3320 Galena Drive, Apt. 101, Frederick, Maryland 21704 (US). **MACIAG, Anna Elzbieta**; 9214 Charterhouse Road, Frederick, Maryland 21704 (US). **SIMANSHU, Dhirendra Kumar**; 3902 Sweet Briar Lane, Frederick, Maryland 21704 (US). **CHAN, Albert Hay Wah**; 8016 Broken Reed Court, Frederick, Maryland 21701 (US). **LIAO, Tao**; 3726 Sprigg Street N., Frederick, Maryland 21704 (US). **BRASSARD, Christopher John**; 2229 Wetherburne Way, Frederick, Maryland 21702 (US). **YANG, Yue**; c/o Lawrence Livermore National Security, LLC, 7000 East Avenue, P.O. Box 808, L-703, Livermore, California 94550 (US). **BISIGNANO, Paola**; c/o Lawrence Livermore National Security, LLC, 7000 East Avenue, P.O. Box 808, L-703, Livermore, California 94550 (US). **LIGHTSTONE, Felice**; c/o Lawrence Livermore National Security, LLC, 7000 East Avenue, P.O. Box 808, L-703, Livermore, California 94550 (US).

(74) Agent: **D'AMATO, Erica M.** et al.; CHOATE, HALL & STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITION OF RAS

(57) Abstract: Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulating (e.g., inhibiting) KRAS (e.g., KRAS having a G12C mutation) and treating diseases or disorders such as cancers in subjects in need thereof.



WO 2023/004102 A2